JNCASR transfers IP rights on potential cure for dementia

A Bengaluru based advanced research centre has agreed to transfer the intellectual property rights of two of its technologies — a molecule that could be a potential cure for dementia and a mobile group oxygen concentrator.
The Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), an autonomous institute under the government’s Department of Science and Technology, signed the IP Transfer Agreements with a Delhi-based company, Hamsa Biopharma, and its own startup initiative, Rugn Abhilekha, on May 11.
Professor T Govindaraju, a scientist at JNCASR, and his team have developed a molecule that could be a potential drug candidate to halt or cure the leading cause of dementia worldwide. This research work was patented and published in the journal Advanced Therapeutics and patented by the JNCASR.
Prof Govindaraju stated that the molecule, named TGR63, can rescue neuronal cells from amyloid toxicity. We saw that the molecule helped in reducing the clumping and slowly reversing the cognitive decline, which disrupts the mechanism through which neurons become dysfunctional due to Alzheimer’s, he added.
JNCASR in a statement said, As per studies, Alzheimer’s will soon be one of the top diseases in the country, and currently available treatments provide only temporary relief, and there are no approved drugs that directly act on the mechanisms of the disease. This molecule addresses the unmet need to develop drug candidates to halt or cure the disease.